Xeris Biopharma files New Jersey patent suits after KEVEYIS patent grant
Bitget2026/10/14 11:08- Xeris Biopharma filed patent infringement suits on Oct. 13, 2026 in New Jersey federal court tied to KEVEYIS (dichlorphenamide).
- Actions follow issuance of U.S. Patent No. 12,758,502 covering the product.
- Claims target proposed generic dichlorphenamide products, alleging infringement through making, selling, or importing.
- Relief sought includes an injunction, monetary damages, enhanced damages, attorneys’ fees, and costs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

Why Nintendo Stock Is One to Watch Ahead of the Holiday Season

A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.

Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.